Israel's ITGI Medical has completed development of its next-generation AneuGraftDX pericardium-covered stent, which has received EU CE Mark certification for sales. ITGI's share price rose 4.9 percent on the news, according to Globes.
As Globes reports, the new stents have a narrower diameter than their predecessors. They're suitable for insertion through the radial artery, which is narrower than the femoral artery. Furthermore, they are easier to sterilize and don't require prior preparation for catheterization procedures. The company thinks these stents could be cheaper to produce than currently available ones.
ITGI specializes in the research and development, design, manufacture and distribution of heterologous tissue-covered stents for cardiovascular and neurovascular interventions, according to the ITGI website. Back in 2007, the company had its initial public offering on the Tel Aviv stock exchange. The IPO allowed the company to develop and mass manufacture a pericardium-covered stent.
Late last month, the company reported that six months after the stent was implanted, the artery was still open and the blood was flowing normally, according to Globes.
- get more from Globes